Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06922474
Active, not recruiting Observational

Molecular Epidemiology of Enteroviruses Detected at the Virology Laboratory of Brest University Hospital During the Period 2018-2024: Retrospective Analysis of an Atypical Meningitis Epidemic in 2024 (BrEcho9Men)

NCT06922474 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Observational
Started
2025-03-01
Last updated
2025-04-10

Condition(s) studied

Enterovirus InfectionsMeningitis, ViralMeningitis EnterovirusEchovirus 9

Study summary

This study is being done to learn more about enterovirus infections detected in the cerebrospinal fluid of patients at CHU de Brest. Researchers will analyze medical records and laboratory data collected between 2018 and 2024. They will look at how these infections present in patients, and whether a specific virus type, called Echo-9, may be associated with different clinical features or represent an emerging variant.

Eligibility

Sex
ALL
Min age
0 Days
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Cerebrospinal fluid (CSF) sample positive for enterovirus by RT-PCR between January 1, 2018 and December 31, 2024 , performed at the virology laboratory of CHU de Brest. * No documented opposition to the use of medical data for research purposes. Exclusion Criteria: * Patients under legal protection (guardianship, curatorship, etc.) * Refusal to participate in the study

Primary outcome measure(s)

  • Phylogenetic analysis of Echo-9 strains detected between 2018 and 2024 — January 1, 2018 to December 31, 2024
    Molecular characterization and phylogenetic comparison of Echo-9 strains detected at CHU de Brest and throughout France between January 1, 2018 and December 31, 2024, to identify a possible emerging variant.

Trial sites (1)

FacilityCityRegionStatus
Chu Brest Brest France

More University Hospital, Brest trials in France

Study on the Priorities of Patients Admitted to Intensive Care Starting soon
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP) Recruiting
Interest of Cryotherapy in Reducing Pain During Radial Arterial Blood Sampling Starting soon
Study of Alloknesia in Atopic Dermatitis Recruiting
Validation of a Method of Screening for Sleep Disorders in Children With Cerebral Palsy, Using Connected Tools Recruiting

Other trials for the same condition

Surveillance of HFMD in Pediatric Outpatients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06922474 on ClinicalTrials.gov ↗ ← All trials in France